DICE Therapeutics, Inc. (DICE)

NASDAQ: DICE · IEX Real-Time Price · USD
16.86 -0.50 (-2.88%)
Jan 14, 2022 4:00 PM EST - Market closed
Market Cap644.58M
Revenue (ttm)863,000
Net Income (ttm)-35.06M
Shares Out38.23M
EPS (ttm)-11.12
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume202,576
Open17.04
Previous Close17.36
Day's Range16.06 - 18.23
52-Week Range16.06 - 40.50
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About DICE

DICE Therapeutics is a biopharmaceutical company leveraging our proprietary DELSCAPE platform to design and develop a pipeline of wholly-owned oral small molecule therapeutics against validated biologic targets to address chronic diseases in immunology and other therapeutic areas. In collaboration with Sanofi, we are also developing a therapeutic candidate for immuno-oncology indications. We believe there is a significant unmet medical need for convenient oral therapies in chronic immunological diseases that offer the therapeutic benefits of sy...

IndustryBiotechnology
IPO DateSep 15, 2021
CEOJ. Kevin Judice, Ph.D.
Employees40
Stock ExchangeNASDAQ
Ticker SymbolDICE
Full Company Profile

Financial Performance

Financial Statements

News

DICE Therapeutics to Present at November Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of n...

1 month ago - GlobeNewsWire

DICE Therapeutics Reports Third Quarter 2021 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of n...

2 months ago - GlobeNewsWire

DICE Therapeutics Initiates Phase 1 Clinical Trial of S011806 for the Treatment of Psoriasis

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of n...

2 months ago - GlobeNewsWire